<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02046655</url>
  </required_header>
  <id_info>
    <org_study_id>UHR-11</org_study_id>
    <nct_id>NCT02046655</nct_id>
  </id_info>
  <brief_title>Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI</brief_title>
  <official_title>Corifollitropin Alfa Compared to Daily Rec FSH in Poor Responders Undergoing ICSI Using a GnRH Antagonist Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <authority>Greece: Ministry of Health and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corifollitropin alfa has been shown to result in significantly more oocytes compared to
      daily recombinant follicle stimulating hormone (recFSH) (Devroey et al., 2009), probably due
      to the higher circulating FSH activity during the first days of stimulation. For this
      reason, the use of corifollitropin alfa might be beneficial in poor responders in whom the
      number of oocytes retrieved  is crucial for success.

      The purpose of this study is to evaluate the effectiveness of corifollitropin alfa treatment
      compared to daily recFSH in terms of the number of oocytes retrieved in a defined population
      of poor responder patients undergoing intracytoplasmic sperm injection (ICSI) using
      gonadotrophin releasing hormone (GnRH) antagonists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Total number of retrieved oocytes</measure>
    <time_frame>36 h after human chorionic gonadotrophin (hCG) administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate (evidence of intrauterine sac with fetal heart activity at 6-8 weeks of gestation)</measure>
    <time_frame>At 6-8 weeks of gestation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos transferred</measure>
    <time_frame>2 days following oocyte retrieval</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Corifollitropin alfa group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa  (Elonva) will be administered.
GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.
A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.
Triggering of final oocyte maturation will be performed using 250 μg of rechCG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rec FSH group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On day 2 of the cycle, daily  SC dose of min 450 IU recFSH (Puregon) will be administered.
GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.
Triggering of final oocyte maturation will be performed using 250 μg of rechCG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corifollitropin alfa</intervention_name>
    <arm_group_label>Corifollitropin alfa group</arm_group_label>
    <other_name>Elonva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH</intervention_name>
    <arm_group_label>rec FSH group</arm_group_label>
    <other_name>Puregon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Proven poor responders of couples with an indication for COS

          2. ≥ 18 and &lt; 45 years of age

          3. BMI ≥ 18 and ≤ 32 kg/m2

          4. Regular spontaneous menstrual cycle (24-35 days)

          5. Availability of ejaculatory sperm (use of donated and/or cryo-preserved sperm is
             allowed)

        Exclusion Criteria:

          1. PGD or PGS

          2. TESE
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Efstratios M Kolibianakis, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit for Human Reproduction, 1st Dept. of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>December 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>E.M. Kolibianakis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
